The PFNT Facility is a coherent set of exploration tools in neurobiology allowing research at the molecular, cellular and integrated levels.
In the context of the Euronanomed projects for Action on Nanomedicine under Horizon 2020, a Symposium will be held at the Luminy campus in Marseille on March 8, 2019. Dr. Khrestchatisky will give a talk titled "Molecular vectors for drug delivery into the brain and tumors".
For more information, please visit the symposium website or download the pdf version of the program.
In an interview published by "La Provence" on November 30, 2018 Yvon Bertrand, President of Aix-Marseille University, explains that AMU is very proud of its contribution to the field of Artificial Intelligence but also to the development of companies such as "First Light Imaging", VECT-HORUS or Innate-Pharma. They are real success stories from public research.
INP Cytoskeleton and Neurophysiopathology team, together with several leading groups in tau biology, has participated in a joint review of the field that just came out in Acta Neuropathologica Communications. This review summarizes the recent breakthroughs in deciphering the molecular structures, both physiological and pathological, of the elusive protein tau.
Read online (open access) : https://link.springer.com/article/10.1186/s40478-019-0682-x
Title : The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention?
The last work of team 9 "Tau regulates the microtubule-dependent migration of glioblastoma cells via Rho-ROCK signaling pathway" is now published in J. cell. Science. This work identifies for the first time the role and mechanisms implicating the tau protein in the invasion processes of glioblastomas, very aggressive brain tumors. This work highlights the role of the Tau protein as a common target between cancers and neurodegeneration.
Professor of Biophysics and Biomathematics at the Faculty of Pharmacy of Marseille, Hervé Kovacic is elected for a six-year term. Section CNU 85 manages the qualifications, promotions and bonuses of teacher-researchers specializing in physicochemical sciences and applied engineering in health. Doctor Pascale Barbier, also from team 9 of INP has been nominated as a member of the same CNU section.
Jean-Michel Paumier, former PhD student in Team 1 (Neural Plasticity and Degeneration), has successfuly defended his thesis on Wednesday the 05th of December 2018. After few hours of a nice presentation followed by many questions, the examining board congratulated Jean-Michel for his good work and granted him the diploma of doctor in Neuroscience.
On December 6 and 7, 2018, Neuroschool PhD Days took place. In this edition entitled "Through the looking glass: beyond our reality", second-year neuroscience PhD students were invited to present their work.
It is in this context that the 3 PhD students of the INP took part: Laurie Arnaud, Audrey Jacq and Dominika Pilat.
Vect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The goal of this collaboration is to use Vect-Horus’ proprietary technology to transport various Janssen monoclonal antibodies to the brain for the treatment of neurodegenerative diseases. This deal was facilitated by Johnson & Johnson Innovation Limited.
On December 6 and 7, 2018, Neuroschool PhD Days took place. In this edition entitled "Through the looking glass: beyond our reality", second-year neuroscience PhD students were invited to present their work.
It is in this context that the 3 PhD students of the INP took part: Laurie Arnaud, Audrey Jacq and Dominika Pilat.
Vect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The goal of this collaboration is to use Vect-Horus’ proprietary technology to transport various Janssen monoclonal antibodies to the brain for the treatment of neurodegenerative diseases. This deal was facilitated by Johnson & Johnson Innovation Limited.
The first conference entitled “Alzheimer’s disease, fears and hopes” was given at the meeting of the management boards of the french Vaincre l’Alzheimer and the german Alzheimer Forschung Initiative foundations that was held on November 16th 2018 at the Novotel Hotel Marseille Vieux Port.
The latest work from the Neural Degeneration and Plasticity team, in collaboration with the BBB and neuroinflammation team of Michel Khrestchatisky: "The pro-amyloidogenic effects of Membrane-type 1-Matrix Metalloproteinase involve MMP-2 and BACE-1 activities, and the modulation of APP trafficking" is now published in the FASEB Journal (doi: 10.1096/fj.201801076R).
Géraldine Ferracci, manager of the Surface Plasmon Resonance unit at INP's Plateform Interactome Neuro-Timone (PINT), gave a talk at the 6th Biacore Users' Meeting.
Vect-Horus has established a long-term highly efficient collaboration with the Institute of NeuroPhysiopathology INP (UMR7051 CNRS-AMU) directed by Dr. Michel KHRESTCHATISKY, cofounder of the company, and this Partnership signed on November 14, 2018 is a cornerstone in the creation of the LABCOM (Common Research Lab) between the INP and Vect-Horus.
The latest work of the NeuroCyto Team (previously on bioRxiv) is now published in the Journal of Cell Biology. We collaborated with the Roy lab to reveal a new mechanism of slow axonal transport, based on the previous discovery of actin hotspots and trails. Hotspots are static actin clusters that appear and disappear within minutes every 3-4 µm along the axon.
On Friday, November 23, the INP welcomes Professor Emeritus Jean-Michel SCHERRMANN (University of Paris Descartes), for a seminar entitled "Why it is difficult to develop CNS drugs: lack of neuropharmacokinetic considerations?”
Santiago Rivera represented the INP on the 1st Congress of the 7 CoENs (International Neetwork of Centers of Excellence in Neurodegeneration) held in Montpellier on October 18 and 19, 2018, endorsed by AVIESAN: Bordeaux, Grenoble, Lille, Montpellier, Marseille, Paris and Toulouse. He gave a lecture in the CoEN Pathfinder laureates’ session entitled MT-MMPs at the crossroads of amyloidogenesis and neuroinflammation in Alzheimer's disease.
The Emergence project entitled “Tau, from Alzheimer disease to glioblastoma, evolution of a prognostic marker” was selected by the Canceropole PACA to be founded by the GEFLUC (groupement des entreprises françaises dans la lutte contre le cancer). Team 9 has a long-time expertise on Tau and this grant will be used to complete the identification of the kinases responsible for Tau phosphorylation in glioblastoma.
Photo from the GEFLUC
Aix Marseille Université | All rights reserved - Legal notice
